Phase 3 N=484 Denosumab China Phase III Study
Osteoporosis, Postmenopausal
Primary: Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine at Month 12 — 5.22; 0.79 Percentage change — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=40 ADAM-Afatinib Diarrhea Assessment and Management
Carcinoma, Non-Small-Cell Lung
Primary: Occurence of CTCAE Grade >= 2 Diarrhea — 72.20; 31.80 Percentage of participants
N/A N=160 Effectiveness of Four Popular Diet Strategies for Weight Loss and Cardiac Risk Reduction
Obesity · Cardiovascular Disease · Metabolic Syndrome
Primary: Weight Loss — -2.1; -3.2; -3.0; -3.3 kg
Phase 2 N=138 A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants Who Achieved American College of Rheumatology 20 (ACR20) Responses at Day 169 — 65.6; 62.0 percentage of participants — p=0.666
Phase 1 N=24 Intracavernosal Injection of Botulinum Toxin Type A in the Treatment of Vascular Erectile Dysfunction
Vasculogenic Erectile Dysfunction
Primary: Cavernosal Artery Mean PSV Before Treatment — 24.5; 28.2 cm/s
Phase 2 N=98 Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients
Gastrointestinal Diseases
Primary: Maximum Tolerated Dose (MTD) — 50 mg/m^2
Phase 2 N=21 Acupuncture for Chemo-Induced Peripheral Neuropathy
Lymphoma · Myeloma · Peripheral Neuropathy
Primary: Mean Neuropathy Severity Score (FACT-GOG-Ntx Total Score Assessment) — 20.8; 16.7; 9.9; 13.2 units on a scale
N/A N=462 Analgesic Treatment for Cancer Pain in South East Asia
Pain
Primary: Prescription Pattern of Analgesics (Opioid or Non-opioid) — 37.27; 11.33; 51.40 percentage of patients
Phase 3 N=499 A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL at Week 48 — 82; 71 Percentage of participants — p=0.005
Phase 3 N=63 A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients
Cytomegalovirus Infections
Primary: Mean Area Under the Concentration-Time Curve From 0 to 24 Hours of Valganciclovir — 65.2; 55; 50; 69.4 mcg*hr/mL
Phase 2 N=25 A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection
Malaria
Primary: Minimum Inhibitory Concentration (MIC) of KAE609
N/A N=64 Mid-term Outcomes of First MTP Arthroplasty With Primus™ FGT Implant.
Hallux Limitus of Left Great Toe · Rheumatoid Arthritis · Arthritis of 1st Metatarsophalangeal Joint
Primary: AOFAS Hallux-MTP-IP Score - Overall — 88.9 units on a scale
Phase 3 N=120 Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
Anal Cancer · Neoplasm of Uncertain Malignant Potential · Nonneoplastic Condition
Primary: Complete Response Through 1 Year — 38; 16 participants
Phase 3 N=3,556 Preventing Sexual Transmission of HIV With Anti-HIV Drugs
HIV Infections
Primary: Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms — 0.07; 1.03 event rate per 100 person-yr — p=<0.0001
N/A N=101 Pentax Airway Scope (AWS) Intubation
Obesity
Primary: Time to Intubation — 26; 38 seconds — p=<0.001